{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:23:53Z","timestamp":1787318633928,"version":"build-2736575974"},"reference-count":39,"publisher":"Pharmaceutical Society of Japan","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,9,20]]},"DOI":"10.1248\/bpb.b25-00137","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T22:08:00Z","timestamp":1758319680000},"page":"1419-1427","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Safety Characteristic of Iguratimod: A Pharmacovigilance Study Based on the Japanese Adverse Drug Event Report (JADER) Database"],"prefix":"10.1248","volume":"48","author":[{"given":"Yanhong","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Yunnan Maternal and Child Health Hospital, No. 200 Gulou Road, Wuhua District, Kunming 650051, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Yunnan Maternal and Child Health Hospital, No. 200 Gulou Road, Wuhua District, Kunming 650051, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Nozaki Y. Iguratimod: novel molecular insights and a new csDMARD for rheumatoid arthritis, from Japan to the world. <i>Life<\/i> (Basel), <b>11<\/b>, 457 (2021).","DOI":"10.3390\/life11050457"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Tanaka K, Yamaguchi T, Hara M. Iguratimod for the treatment of rheumatoid arthritis in Japan. <i>Expert Rev. Clin. Immunol.<\/i>, <b>11<\/b>, 565\u2013573 (2015).","DOI":"10.1586\/1744666X.2015.1027151"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Zeng L, He Q, Deng Y, Li Y, Chen J, Yang K, Luo Y, Ge A, Zhu X, Long Z, Sun L. Efficacy and safety of iguratimod in the treatment of rheumatic and autoimmune diseases: a meta-analysis and systematic review of 84 randomized controlled trials. <i>Front. Pharmacol.<\/i>, <b>14<\/b>, 1189142 (2023).","DOI":"10.3389\/fphar.2023.1189142"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Long Z, Zeng L, Yang K, Chen J, Luo Y, Dai CC, He Q, Deng Y, Ge A, Zhu X, Hao W, Sun L. A systematic review and meta-analysis of the efficacy and safety of iguratimod in the treatment of inflammatory arthritis and degenerative arthritis. <i>Front. Pharmacol.<\/i>, <b>15<\/b>, 1440584 (2024).","DOI":"10.3389\/fphar.2024.1440584"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Hara M, Abe T, Sugawara S, Mizushima Y, Hoshi K, Irimajiri S, Hashimoto H, Yoshino S, Matsui N, Nobunaga M. Long-term safety study of iguratimod in patients with rheumatoid arthritis. <i>Mod. Rheumatol.<\/i>, <b>17<\/b>, 10\u201316 (2007).","DOI":"10.1007\/s10165-006-0543-x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Mimori T, Harigai M, Atsumi T, Fujii T, Kuwana M, Matsuno H, Momohara S, Takei S, Tamura N, Takasaki Y, Ikeuchi S, Kushimoto S, Koike T. Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan. <i>Mod. Rheumatol.<\/i>, <b>27<\/b>, 755\u2013765 (2017).","DOI":"10.1080\/14397595.2016.1265695"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Sendaydiego X, Gold LS, Dubreuil M, Andrews JS, Reid P, Liew DFL, Goulabchand R, Singh AG, Hughes GC, Pioro M, Sparks JA, Jarvik JG, Singh S, Liew JW, Singh N. Use of biologic or targeted synthetic disease-modifying antirheumatic drugs and cancer risk. <i>JAMA Netw. Open<\/i>, <b>7<\/b>, e2446336 (2024).","DOI":"10.1001\/jamanetworkopen.2024.46336"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Xiong W, Li Y, Hu L, He G, Huang J. Risks of malignancies related to disease-modifying antirheumatic drugs in rheumatoid arthritis: a pharmacovigilance analysis using the FAERS database. <i>Front. Pharmacol.<\/i>, <b>15<\/b>, 1458500 (2024).","DOI":"10.3389\/fphar.2024.1458500"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Yamada T, Ogawa T, Tanaka T, Kusaka Y, Nishihara M, Ashida A. Disproportionality analysis of amenamevir-induced encephalopathy using the Japanese adverse drug event report database. <i>J. Infect. Chemother.<\/i>, <b>31<\/b>, 102519 (2024).","DOI":"10.1016\/j.jiac.2024.09.008"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Yamaoka K, Fujiwara M, Uchida M, Uesawa Y, Muroi N, Shimizu T. Comprehensive analysis of adverse events induced by PARP inhibitors using JADER and time to onset. <i>Life<\/i> (Basel), <b>12<\/b>, 1355 (2022).","DOI":"10.3390\/life12091355"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Motoishi H, Uesawa Y, Ishii-Nozawa R. Evaluation of \u03b2-blocker-induced bradyarrhythmia using an analysis of the Japanese Adverse Drug Event Report database. <i>Biol. Pharm. Bull.<\/i>, <b>47<\/b>, 1668\u20131674 (2024).","DOI":"10.1248\/bpb.b24-00305"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Ide N, Sako KI, Takigawa M, Tanaka H. Risk and time-to-onset of acute kidney injury with vancomycin plus piperacillin-tazobactam combination: analysis using JADER. <i>In Vivo<\/i>, <b>38<\/b>, 1436\u20131442 (2024).","DOI":"10.21873\/invivo.13586"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Tsuchiya M, Obara T, Sakai T, Nomura K, Takamura C, Mano N. Quality evaluation of the Japanese Adverse Drug Event Report database (JADER). <i>Pharmacoepidemiol. Drug Saf.<\/i>, <b>29<\/b>, 173\u2013181 (2020).","DOI":"10.1002\/pds.4944"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Mozzicato P. Standardised MedDRA queries: their role in signal detection. <i>Drug Saf.<\/i>, <b>30<\/b>, 617\u2013619 (2007).","DOI":"10.2165\/00002018-200730070-00009"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Fusaroli M, Salvo F, Begaud B, <i>et al<\/i>. The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement. <i>Drug Saf.<\/i>, <b>47<\/b>, 575\u2013584 (2024).","DOI":"10.1007\/s40264-024-01421-9"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Fusaroli M, Salvo F, Begaud B, <i>et al<\/i>. The REporting of a disproportionality analysis for DrUg safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration. <i>Drug Saf.<\/i>, <b>47<\/b>, 585\u2013599 (2024).","DOI":"10.1007\/s40264-024-01423-7"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Zou F, Zhu C, Lou S, Cui Z, Wang D, Ou Y, Wang L, Chen J, Lan Y. A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database. <i>Front. Pharmacol.<\/i>, <b>14<\/b>, 1320458 (2023).","DOI":"10.3389\/fphar.2023.1320458"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. <i>Int. J. Med. Sci.<\/i>, <b>10<\/b>, 796\u2013803 (2013).","DOI":"10.7150\/ijms.6048"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Abe J, Umetsu R, Mataki K, Kato Y, Ueda N, Nakayama Y, Hane Y, Matsui T, Hatahira H, Sasaoka S, Motooka Y, Hara H, Kato Z, Kinosada Y, Inagaki N, Nakamura M. Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese Adverse Drug Event Report database. <i>J. Pharm. Health Care Sci.<\/i>, <b>2<\/b>, 14 (2016).","DOI":"10.1186\/s40780-016-0048-5"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Kinoshita S, Hosomi K, Yokoyama S, Takada M. Time-to-onset analysis of amiodarone-associated thyroid dysfunction. <i>J. Clin. Pharm. Ther.<\/i>, <b>45<\/b>, 65\u201371 (2020).","DOI":"10.1111\/jcpt.13024"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Sauzet O, Carvajal A, Escudero A, Molokhia M, Cornelius VR. Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data. <i>Drug Saf.<\/i>, <b>36<\/b>, 995\u20131006 (2013).","DOI":"10.1007\/s40264-013-0061-7"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Nakamura M, Umetsu R, Abe J, Matsui T, Ueda N, Kato Y, Sasaoka S, Tahara K, Takeuchi H, Kinosada Y. Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events. <i>J. Pharm. Health Care Sci.<\/i>, <b>1<\/b>, 34 (2015).","DOI":"10.1186\/s40780-015-0035-2"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Kyotani Y, Zhao J, Nakahira K, Yoshizumi M. Analysis of appendicitis cases in the Japanese Adverse Drug Event Report (JADER) database. <i>Biol. Pharm. Bull.<\/i>, <b>46<\/b>, 655\u2013660 (2023).","DOI":"10.1248\/bpb.b22-00670"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Cecco S, Puligheddu S, Fusaroli M, Gerratana L, Yan M, Zamagni C, De Ponti F, Raschi E. Emerging toxicities of antibody-drug conjugates for breast cancer: clinical prioritization of adverse events from the FDA adverse event reporting system. <i>Target. Oncol.<\/i>, <b>19<\/b>, 435\u2013445 (2024).","DOI":"10.1007\/s11523-024-01058-9"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Gatti M, Antonazzo IC, Diemberger I, De Ponti F, Raschi E. Adverse events with sacubitril\/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system. <i>Eur. J. Prev. Cardiol.<\/i>, <b>28<\/b>, 983\u2013989 (2021).","DOI":"10.1177\/2047487320915663"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Mori S, Sugimoto M. <i>Pneumocystis jirovecii<\/i> pneumonia in rheumatoid arthritis patients: risks and prophylaxis recommendations. <i>Clin. Med. Insights Circ. Respir. Pulm. Med.<\/i>, <b>9<\/b> (Suppl. 1), 29\u201340 (2015).","DOI":"10.4137\/CCRPM.S23286"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Kourbeti IS, Ziakas PD, Mylonakis E. Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis. <i>Clin. Infect. Dis.<\/i>, <b>58<\/b>, 1649\u20131657 (2014).","DOI":"10.1093\/cid\/ciu185"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Ohmura SI, Homma Y, Masui T, Miyamoto T. Factors associated with <i>Pneumocystis jirovecii<\/i> pneumonia in patients with rheumatoid arthritis receiving methotrexate: a single-center retrospective study. <i>Intern. Med.<\/i>, <b>61<\/b>, 997\u20131006 (2022).","DOI":"10.2169\/internalmedicine.8205-21"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. <i>JAMA<\/i>, <b>301<\/b>, 737\u2013744 (2009).","DOI":"10.1001\/jama.2009.146"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Singh N, Li CI. Impact of rheumatoid arthritis and biologic and targeted synthetic disease modifying antirheumatic agents on cancer risk and recurrence. <i>Curr. Opin. Rheumatol.<\/i>, <b>33<\/b>, 292\u2013299 (2021).","DOI":"10.1097\/BOR.0000000000000796"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Huss V, Bower H, Hellgren K, Frisell T, Askling J, Ahlenius G-M, Baecklund E, Chatzidionysiou K, Feltelius N, Forsblad-d\u2019Elia H, Kastbom A, Klareskog L, Lindqvist E, Lindstr\u00f6m U, Turesson C, Sj\u00f6wall C, Askling J. Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study. <i>Ann. Rheum. Dis.<\/i>, <b>82<\/b>, 911\u2013919 (2023).","DOI":"10.1136\/ard-2022-223636"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Sepriano A, Kerschbaumer A, Bergstra SA, Smolen JS, van der Heijde D, Caporali R, Edwards CJ, Verschueren P, de Souza S, Pope J, Takeuchi T, Hyrich K, Winthrop KL, Aletaha D, Stamm T, Schoones JW, Landew\u00e9 RBM. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Ann. Rheum. Dis.<\/i>, <b>82<\/b>, 107\u2013118 (2023).","DOI":"10.1136\/ard-2022-223357"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Nakagawa C, Ota R, Hirata A, Yokoyama S, Uno T, Hosomi K. Reasons and predictors of treatment change in rheumatoid arthritis patients treated with biological and targeted synthetic disease-modifying antirheumatic drugs: a single-center retrospective observational study. <i>Biol. Pharm. Bull.<\/i>, <b>47<\/b>, 1759\u20131767 (2024).","DOI":"10.1248\/bpb.b24-00366"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) De Cock D, Hyrich K. Malignancy and rheumatoid arthritis: epidemiology, risk factors and management. <i>Best Pract. Res. Clin. Rheumatol.<\/i>, <b>32<\/b>, 869\u2013886 (2018).","DOI":"10.1016\/j.berh.2019.03.011"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Yang M, Su Y, Xu K, Xie J, Wen P, Liu L, Yang Z, Xu P. Rheumatoid arthritis increases the risk of malignant neoplasm of bone and articular cartilage: a two-sample bidirectional mendelian randomization study. <i>Arthritis Res. Ther.<\/i>, <b>25<\/b>, 219 (2023).","DOI":"10.1186\/s13075-023-03205-5"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Lee H. The risk of malignancy in Korean patients with rheumatoid arthritis. <i>Yonsei Med. J.<\/i>, <b>60<\/b>, 223\u2013229 (2019).","DOI":"10.3349\/ymj.2019.60.2.223"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. <i>Arthritis Res. Ther.<\/i>, <b>17<\/b>, 212 (2015).","DOI":"10.1186\/s13075-015-0728-9"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Sakai T. Role and applicability of spontaneous reporting databases in medical big data. <i>Yakugaku Zasshi<\/i>, <b>141<\/b>, 165\u2013168 (2021).","DOI":"10.1248\/yakushi.20-00196-1"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Shu Y, Ding Y, Liu L, Zhang Q. Cardiac adverse events associated with quetiapine: disproportionality analysis of FDA adverse event reporting system. <i>CNS Neurosci. Ther.<\/i>, <b>29<\/b>, 2705\u20132716 (2023).","DOI":"10.1111\/cns.14215"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/9\/48_b25-00137\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T04:02:06Z","timestamp":1758340926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/9\/48_b25-00137\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,20]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00137","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,20]]},"article-number":"b25-00137"}}